Second European Stelara Biosimilar Pits Sandoz Against Stada

Sandoz Launches Samsung Bioepis-Partnered Pyzchiva Ustekinumab Rival Across Europe

Just days after the first European ustekinumab biosimilar launch, Sandoz has entered the fray with the second rival to Stelara, introducing its Samsung Bioepis-partnered Pyzchiva version to compete with Stada and Alvotech’s Uzpruvo.

Player One vs Player Two graphic
Sandoz and Stada are facing off in Europe over ustekinumab • Source: Shutterstock

Sandoz has confirmed the European launch of its Pyzchiva (ustekinumab) biosimilar rival to Stelara. The introduction of the Samsung Bioepis-partnered biosimilar comes just days after Stada and Alvotech’s Uzpruvo version hit the market at the start of this week.

Pyzchiva – which was approved in Europe earlier this year (Also see "Sandoz And Samsung Celebrate Stelara Rival’s EU...

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.